C2C

 

Title: C2C: COMBINE-2 for Cabotegravir+Rilpivirine LA Regimen - A Prospective Cohort Study to Monitor Effectiveness, Adherence and Resistance

Sites: Ongoing 
Territories: UK, Belgium, France, Germany, Italy, Netherlands, Spain, Switzerland & Sweden
Status: Ongoing, open to recruitment

​

Abstract presented as poster at EACS 2023 - Real-World Effectiveness of Cabotegravir + Rilpivirine in Virologically Suppressed Treatment Experienced Individuals in Europe:  Data from COMBINE-2 Study

​

​